Categories
FAQ Myeloproliferative neoplasms (MPNs) Patient Events

Understanding MPN Biomarkers: JAK2, CALR, MPL & More

Andrew Schorr (MPN patient advocate) sits down with Dr. Angela Fleischman (University of California, Irvine) to unpack what JAK2, CALR, and MPL mean for MPN diagnosis and everyday care. They also explain how added findings (ASXL1, IDH1/2, EZH2), next-generation sequencing (NGS), and risk scores can inform treatment choices and clinical trials.

MPN Biomarkers with Dr. Angela Fleischman and MPN patient advocate Andrew Schorr

Understanding MPN Biomarkers: JAK2, CALR, MPL & More

What Mutations Reveal About Your Diagnosis, Prognosis & Treatment Options

Wednesday, October 22, 2025, at 5 p.m. PT / 8 p.m. ET

Biomarkers can be confusing. This program makes them clear. Well-known MPN patient advocate, Andrew Schorr, interviews Dr. Angela Fleischman (UC Irvine) about how common mutations (JAK2, CALR, MPL) help confirm an MPN and what they can (and can’t) predict about symptoms and clotting risk. They discuss when “watch and wait” is right and when to consider medicines like interferon or JAK inhibitors.

You’ll also learn how high-risk mutations (ASXL1, IDH1/2, EZH2) may affect transplant discussions, why results can change over time (clonal evolution), and how NGS is shaping more personalized monitoring. Practical takeaways help you talk with your care team and explore clinical trials with confidence.

Program Topics

  • Biomarker Basics: What JAK2, CALR, and MPL show and how blood tests find them
  • Treatment Decisions: When watch-and-wait, interferon, or JAK inhibitors make sense
  • High-Risk Mutations: How ASXL1/IDH1/2/EZH2 can guide closer follow-up or transplant talks
  • Clonal Evolution & NGS: Why results change over time and how sequencing tracks it
  • Personalized Care & Trials: Using risk scores (e.g., DIPSS/MIPSS) and clinical trials to tailor options